MedTrace Logo

CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors

NCT07335497 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 290

Last updated 2026-05-06

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and tolerability of monotherapy CR-001 and identify the maximum tolerated dose (MTD), and/or optimal biologic dose and Recommended Phase 2 Dose(s) (RP2D) in participants with locally advanced or metastatic solid tumors.

Conditions

  • Locally Advanced / Metastatic Solid Tumors

Interventions

DRUG

CR-001

Intravenous Infusion

Sponsors & Collaborators

  • Crescent Biopharma, Inc.

    lead INDUSTRY

Principal Investigators

  • Brad Sumrow, MD · Crescent Biopharma, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-17
Primary Completion
2029-02-28
Completion
2029-02-28
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07335497 on ClinicalTrials.gov